Melane Sampson, Author at BioTuesdays

Developments

Avicanna and Vectura forge scientific and medical affairs collaboration

Avicanna (TSX:AVCN; OTCQX:AVCNF; FSE:ONN) has announced a scientific and medical affairs collaboration with Vectura Fertin Pharma to establish a joint committee aimed at enhancing the understanding of medical cannabis...

January 16, 2025

Developments

Peer-reviewed journal accepts Spago’s article on trial results for publication

Spago Nanomedical (STO:SPAGO.ST; FRA:7UX.F) announced that its article on the results of the SPANGOPIX-01 clinical trial of pegfosimer manganese (SN132D) for contrast-enhanced MRI of breast cancer has been accepted for...

January 15, 2025

Developments

Vistagen reports positive Phase 2a results for nasal spray in cancer cachexia

Vistagen (NASDAG:VTGN) announced positive results from its exploratory Phase 2a study of PH284, an investigational pherine nasal spray for cancer cachexia— a condition characterized by appetite loss and severe wasting...

January 15, 2025

Developments

Adaptive partners with NeoGenomics to advance blood cancer monitoring

Adaptive Biotechnologies (NASDAQ:ADPT) and NeoGenomics (NASDAQ:NEO) have announced a multi-year exclusive collaboration aimed at advancing minimal residual disease (MRD) monitoring options for patients with select blood...

January 14, 2025

Executive Moves

Terence Tan joins William Blair’s Biopharma Investment Banking Group

William Blair, a global investment firm, has announced the addition of Terence Tan as managing director in its healthcare investment banking team. In this role, Mr. Tan will focus on delivering comprehensive advisory...

January 14, 2025

Feature

ROMTech advancing postoperative rehabilitation with unparalleled patient outcomes

Closely-held ROMTech is combining cutting-edge innovation with advanced telemedicine technology, transforming rehabilitation, diagnostics, facilitating seamless remote patient-physician connections for at-home...

January 14, 2025

Developments

Arrivo unveils positive study results on SP-624’s impact on depression and cognition

Closely held Arrivo BioVentures has announced promising results from its study evaluating SP-624’s novel epigenetic mechanism of action on neurological pathways. According to the company, the findings provide insights...

January 10, 2025

Developments

FDA grants additional FTD to Mersana’s XMT-1660 for breast cancer

Mersana Therapeutics (NASDAQ:MRSN) has announced that the FDA has granted an additional fast track designation (FTD) to its emiltatug ledadotin (XMT-1660) for the treatment of advanced or metastatic breast cancer. The...

January 10, 2025

Developments

Genenta strengthens pact with CDMO to enhance production

Genenta Science (NASDAQ:GNTA) announced that it has amended its development and master services agreement with contract development and manufacturing organization (CDMO) AGC Biologics to bolster production capabilities...

January 10, 2025

Developments

Inspira responds to China’s recent hMPV outbreak; prepares to ramp up production

Inspira Technologies (NASDAQ:IINN) has announced its preparations for a possible increase in production of its INSPIRA ART100 device to address the growing demand for advanced respiratory care technologies following the...

January 10, 2025

Author - Melane Sampson

Avicanna and Vectura forge scientific and medical affairs collaboration

Peer-reviewed journal accepts Spago’s article on trial results for publication

Vistagen reports positive Phase 2a results for nasal spray in cancer cachexia

Adaptive partners with NeoGenomics to advance blood cancer monitoring

Terence Tan joins William Blair’s Biopharma Investment Banking Group

ROMTech advancing postoperative rehabilitation with unparalleled patient outcomes

Arrivo unveils positive study results on SP-624’s impact on depression and cognition

FDA grants additional FTD to Mersana’s XMT-1660 for breast cancer

Genenta strengthens pact with CDMO to enhance production

Inspira responds to China’s recent hMPV outbreak; prepares to ramp up production

Subscribe